TriSalus Life Sciences
TLSI
67 hedge funds and large institutions have $79.8M invested in TriSalus Life Sciences in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 13 reducing their positions, and 8 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 13
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
79% more capital invested
Capital invested by funds: $44.6M → $79.8M (+$35.2M)
12% more funds holding
Funds holding: 60 → 67 (+7)
3.65% more ownership
Funds ownership: 19.22% → 22.88% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.18M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.08M |
| 3 |
Morgan Stanley
New York
|
+$1.94M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.1M |
| 5 |
EFMC
Empire Financial Management Company
New York
|
+$403K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$840K |
| 2 |
Goldman Sachs
New York
|
-$473K |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$381K |
| 4 |
Corient Private Wealth
Miami,
Florida
|
-$352K |
| 5 |
Squarepoint
New York
|
-$164K |
TLSI Hedge Fund Activity: Q4 2025 in Review
67 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2025, worth a combined $79.8M — up 79% from $44.6M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TLSI positions and 8 closed out — a net gain of 7 holders — while 26 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $4.18M. The largest seller was Alyeska Investment Group, cutting an estimated $840K.
- 67 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2025, up from 60 in Q3 2025.
- Funds reported $79.8M of TriSalus Life Sciences stock for Q4 2025, up 79% quarter-over-quarter.
- 15 funds opened new TriSalus Life Sciences positions in Q4 2025 and 8 closed out, a net change of +7 holders.
- The largest TriSalus Life Sciences buyer in Q4 2025 was BlackRock, an estimated $4.18M added.
- The largest TriSalus Life Sciences seller in Q4 2025 was Alyeska Investment Group, an estimated $840K sold.
Based on aggregated 13F filings for Q4 2025.